Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

INTRODUCTION: Patients with Alzheimer's disease (AD) are currently treated with cholinesterase inhibitors, such as galantamine, without actual knowledge of its concentration in plasma. Our objective was to analyse potential relationships between galantamine concentration, galantamine dose, soci...

Descripción completa

Detalles Bibliográficos
Autores principales: Wattmo, Carina, Jedenius, Erik, Blennow, Kaj, Wallin, Åsa K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580330/
https://www.ncbi.nlm.nih.gov/pubmed/23286718
http://dx.doi.org/10.1186/alzrt156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580330/
https://www.ncbi.nlm.nih.gov/pubmed/23286718
http://dx.doi.org/10.1186/alzrt156

Ejemplares similares